Glenmark Pharmaceuticals’ subsidiary, Glenmark Life Sciences, is being considered for a majority stake sale, with several private equity firms expressing preliminary interest. Glenmark Life Sciences specializes in the development and manufacture of active pharmaceutical ingredients (APIs). The final decision on the sale has not yet been made, and the process is still ongoing. The potential for a sale of the API subsidiary has been a topic of discussion for some time.
Private Equity Firms Show Interest in Glenmark Life Sciences Sale
Private equity funds are showing interest in buying a majority stake in Glenmark Life Sciences, an API developer and manufacturer owned by Glenmark Pharmaceuticals. The sale process is still ongoing and no final decision has been made.
Latest from Blog
A new study from Bristol University's Nutrition and Behaviour Group reveals that whole foods like apples
In about a billion years, the sun's expansion will render Earth inhospitable. However, a fortuitous encounter
The 13th week of the 2023 NFL season is underway with a victory for the Cowboys.
A new report reveals that OpenAI's former board intentionally excluded Microsoft amidst ongoing conflicts with CEO
SpaceX launched Ireland's first satellite and a South Korean reconnaissance satellite today. A SpaceX Falcon 9
